VCIM
Velan Capital Investment Management Portfolio holdings
AUM
$99.9M
This Quarter Return
+15.01%
1 Year Return
+37.46%
3 Year Return
+659.14%
5 Year Return
–
10 Year Return
–
AUM
$99.9M
AUM Growth
+$99.9M
(+2.8%)
Cap. Flow
-$2.31M
Cap. Flow
% of AUM
-2.32%
Top 10 Holdings %
Top 10 Hldgs %
70.22%
Holding
57
New
9
Increased
16
Reduced
5
Closed
7
Top Buys
| 1 |
Cidara Therapeutics
CDTX
|
$4.87M |
| 2 |
ALMS
Alumis Inc. Common Stock
ALMS
|
$4.86M |
| 3 |
Arvinas
ARVN
|
$3.68M |
| 4 |
Rezolute
RZLT
|
$1.56M |
| 5 |
Sutro Biopharma
STRO
|
$1.45M |
Top Sells
| 1 |
SLRN
ACELYRIN
SLRN
|
$8.32M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$8.19M |
| 3 |
Praxis Precision Medicines
PRAX
|
$1.5M |
| 4 |
Instil Bio
TIL
|
$1.2M |
| 5 |
Immunome
IMNM
|
$1.03M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Heron Therapeutics
HRTX
$207M
| $14.5M | 14.29% | 6,986,744 | – | – |
|
|
VRNA
2
Verona Pharma
VRNA
$9.16B
| $8.99M | 8.88% | 95,000 | – | – |
|
3
Jasper Therapeutics
JSPR
$45.5M
| $7.96M | 7.86% | 1,433,828 | – | – |
|
4
Protara Therapeutics
TARA
$120M
| $6.48M | 6.4% | 2,139,000 +471,200 | +28% | +$1.43M |
|
5
Zevra Therapeutics
ZVRA
$509M
| $6.3M | 6.22% | 715,000 +50,000 | +8% | +$441K |
|
6
Tourmaline Bio
TRML
$601M
| $6.3M | 6.22% | 393,889 -61,523 | -14% | -$984K |
|
|
7
Praxis Precision Medicines
PRAX
$958M
| $6.28M | 6.2% | 149,334 -35,666 | -19% | -$1.5M |
|
|
8
Cidara Therapeutics
CDTX
$1.66B
| $4.87M | 4.81% | +100,000 | New | +$4.87M |
|
|
ALMS
9
Alumis Inc. Common Stock
ALMS
$479M
| $4.86M | 4.8% | +1,620,846 | New | +$4.86M |
|
|
10
Arvinas
ARVN
$568M
| $3.68M | 3.64% | +500,000 | New | +$3.68M |
|
11
scPharmaceuticals
SCPH
$295M
| $3.5M | 3.45% | 917,668 | – | – |
|
|
12
Rezolute
RZLT
$619M
| $3.35M | 3.3% | 750,000 +350,000 | +88% | +$1.56M |
|
13
Liquidia Corp
LQDA
$2.38B
| $2.98M | 2.94% | 239,260 -60,740 | -20% | -$757K |
|
14
Mineralys Therapeutics
MLYS
$1.03B
| $2.36M | 2.33% | 174,600 +24,000 | +16% | +$325K |
|
|
15
Sutro Biopharma
STRO
$72.7M
| $2.18M | 2.16% | 3,060,000 +2,030,000 | +197% | +$1.45M |
|
16
InspireMD
NSPR
$102M
| $2.05M | 2.03% | 904,029 | – | – |
|
17
Perspective Therapeutics
CATX
$250M
| $1.72M | 1.7% | 500,000 | – | – |
|
18
Replimune Group
REPL
$422M
| $1.7M | 1.68% | 183,083 +1,000 | +0.5% | +$9.29K |
|
19
TELA Bio
TELA
$70.5M
| $1.45M | 1.43% | 747,410 | – | – |
|
20
Edesa Biotech
EDSA
$16.3M
| $1.4M | 1.38% | 687,500 | – | – |
|
21
Viridian Therapeutics
VRDN
$1.5B
| $1.21M | 1.19% | +86,500 | New | +$1.21M |
|
|
UPB
22
Upstream Bio, Inc. Common Stock
UPB
$923M
| $1.17M | 1.16% | 107,000 | – | – |
|
23
Eledon Pharmaceuticals
ELDN
$155M
| $919K | 0.91% | 338,973 +15,000 | +5% | +$40.7K |
|
24
Avalo Therapeutics
AVTX
$122M
| $773K | 0.76% | 154,972 +43,000 | +38% | +$215K |
|
25
Tenax Therapeutics
TENX
$27.3M
| $480K | 0.47% | 83,333 | – | – |
|